NanoVibronix Overview
NanoVibronix develops medical devices based on a proprietary therapeutic ultrasound technology. Its products address a range of clinical applications including catheter-related injuries and their complications, pain, and soft tissue healing. The company's patented technology allows for the creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. The technology can be utilized for a variety of medical applications requiring low-cost ultrasound therapy. The NanoVibronix PainShield device is a wearable, battery-powered electronic unit that uses a disposable patch through which it delivers localized energy, creating a therapeutic effect to relieve localized pain and induce soft tissue healing. PainShield has gained CE Mark certification and also carries FDA clearance. The UroShield system is a multi-targeted solution intended to work with a number of factors essential to preventing catheter-related complications. The device is CE mark certified. The company's WoundShield, designed to accelerate wound healing, may also be used to enhance oxygen and topical drug delivery.
Cumulative Funding Raised Over Time ($)
$5.0MAug 2023
$6.0MDec 2011
$12.0MDec 2020
$14.4MDec 2022
$17.6MJun 2019
$19.1MMar 2015
$19.4MNov 2011
Latest News
growth-positive
NanoVibronix Inc. (NAOV): 2025 Product Pipeline and Strategy Analysis Report
NanoVibronix Inc., headquartered in Elmsford, New York, is advancing its pipeline of medical devices, including pain relief drugs, ultrasound therapy devices, and urology equipment. The companys technology focuses on combating biofilm formation, enhancing antibiotic efficacy, and reducing catheter-related discomfort. Their products, marketed under the brand names UroShield, PainShield, and NanoVibronix, are extensively available in the U.S. and Israel. The report provides a comprehensive analysis of NanoVibronixs product pipeline, detailing the developmental stages, clinical trials, and projected launch dates. It serves as a strategic resource for stakeholders to develop competitive strategies and explore market-entry opportunities.
Product Stage
growth-positive
NanoVibronix Launches "Oscar" Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities
NanoVibronix, Inc., a medical technology company, has launched Oscar, an advanced training aid through its ENvue Medical division. Oscar is designed to standardize and improve training for naso-enteral feeding procedures, addressing a significant barrier to the adoption of new technologies. This initiative is expected to accelerate the adoption of NanoVibronixs ENvue system by reducing onboarding time and resources. The company plans to offer Oscar as a teaching aid and independently to various educational institutions, creating new revenue channels. The broader availability of Oscar is anticipated in 2026, contributing to revenue and expanding growth opportunities.
Product StageCustomers
growth-positive
NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
NanoVibronix, Inc., a medical technology company, has announced a registered direct offering with a single institutional investor for the purchase of 291,204 shares at $7.01 per share. The offering, expected to close on September 17, 2025, is anticipated to generate approximately $2.0 million in gross proceeds. Palladium Capital Group, LLC is acting as the exclusive placement agent. The funds will be used for general working capital, including debt repayment and redemption of preferred stock. This offering is conducted under a shelf registration statement filed with the SEC.
PIPE/PO
growth-positive
NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical’s Intellectual Property Portfolio
NanoVibronix, Inc., a medical technology company, announced the issuance of a new U.S. patent for its subsidiary, ENvue Medical Holdings LLC. The patent, titled Insertion Device Positioning Guidance System and Method, enhances the companys competitive position in medical navigation technology. This patent protects proprietary systems for guiding the insertion of medical devices using electromagnetic positioning technology, improving real-time visualization and accuracy. The patent is seen as a significant milestone, reinforcing NanoVibronixs leadership in the field and supporting its growth strategy. The companys ENvue Navigation Platform is FDA 510(k) cleared for adult use, with potential future expansions.
growth-positive
NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology
NanoVibronix, Inc., a medical technology company, announced the issuance of a new U.S. patent for its subsidiary, ENvue Medical Holdings LLC. The patent covers a proprietary method for overlaying electromagnetic navigation data onto real-time medical imaging, enhancing the precision and efficiency of feeding tube and catheter placements. This development strengthens the companys intellectual property portfolio and positions it for expansion into the vascular navigation market. The ENvue Navigation Platform, which is FDA 510(k) cleared for adult use, provides real-time visualization of tube movement, supporting informed clinical decision-making. The patent is expected to bolster NanoVibronixs leadership in the feeding tube placement market and open new opportunities for growth.
Product Stage
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $24.5M |
| Last funding | $5M |
| Stage | Public |
| Rounds | 9 |
| Investors | 1 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | nanovibronix.com |
Locations
Derech HaShalom 9, Nesher, Israel
525 Executive Blvd Elmsford, NY 10523, USA
Photos & Videos
3 item(s)
NanoVibronix Business
Business models
B2C, B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
SensingAcousticsSimulation & ImagingUltrasoundTags (9)
ultrasoundwearablepain-reliefmedical-devicesurologytherapeutic-devicesmedical-productshome-carenanotechnologyGeographic Markets
EuropeEast AsiaIndiaSoutheast AsiaNorth AmericaNanoVibronix Financials
$24.5M
Total funding
Undisclosed
Capital raised
$5M
Last funding
Public
Funding stage
9
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$5.0MAug 2023
$6.0MDec 2011
$12.0MDec 2020
$14.4MDec 2022
$17.6MJun 2019
$19.1MMar 2015
$19.4MNov 2011
Private Equity Funding
PIPE
Aug 2023
$5M
Undisclosed Investor(s)
PIPE
Dec 2022
$2.4M
Undisclosed Investor(s)
PIPE
Dec 2020
$6M
Undisclosed Investor(s)
PIPE
Jun 2019
$3.2M
Undisclosed Investor(s)
Convertible Debt
Mar 2015
$1.5M
Convertible Debt
Dec 2011
$1M
Seed
Nov 2011
$300K
Public Offering / Exit
POEvent
Nov 2017
Undisclosed
POEvent
Apr 2014
Undisclosed
NanoVibronix Lifecycle
Cumulative Funding Raised Over Time
$5.0MAug 2023
$6.0MDec 2011
$12.0MDec 2020
$14.4MDec 2022
$17.6MJun 2019
$19.1MMar 2015
$19.4MNov 2011
All Events
PIPE
Aug 2023
$5M
Undisclosed Investor(s)
PIPE
Dec 2022
$2.4M
Undisclosed Investor(s)
PIPE
Dec 2020
$6M
Undisclosed Investor(s)
PIPE
Jun 2019
$3.2M
Undisclosed Investor(s)
Convertible Debt
Mar 2015
$1.5M
Convertible Debt
Dec 2011
$1M
Seed
Nov 2011
$300K
POEvent
Nov 2017
Undisclosed
POEvent
Apr 2014
Undisclosed
NanoVibronix News
93 articles
growth-positive
NanoVibronix Inc. (NAOV): 2025 Product Pipeline and Strategy Analysis Report
NanoVibronix Inc., headquartered in Elmsford, New York, is advancing its pipeline of medical devices, including pain relief drugs, ultrasound therapy devices, and urology equipment. The companys technology focuses on combating biofilm formation, enhancing antibiotic efficacy, and reducing catheter-related discomfort. Their products, marketed under the brand names UroShield, PainShield, and NanoVibronix, are extensively available in the U.S. and Israel. The report provides a comprehensive analysis of NanoVibronixs product pipeline, detailing the developmental stages, clinical trials, and projected launch dates. It serves as a strategic resource for stakeholders to develop competitive strategies and explore market-entry opportunities.
Product Stage
growth-positive
NanoVibronix Launches "Oscar" Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities
NanoVibronix, Inc., a medical technology company, has launched Oscar, an advanced training aid through its ENvue Medical division. Oscar is designed to standardize and improve training for naso-enteral feeding procedures, addressing a significant barrier to the adoption of new technologies. This initiative is expected to accelerate the adoption of NanoVibronixs ENvue system by reducing onboarding time and resources. The company plans to offer Oscar as a teaching aid and independently to various educational institutions, creating new revenue channels. The broader availability of Oscar is anticipated in 2026, contributing to revenue and expanding growth opportunities.
Product StageCustomers
growth-positive
NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
NanoVibronix, Inc., a medical technology company, has announced a registered direct offering with a single institutional investor for the purchase of 291,204 shares at $7.01 per share. The offering, expected to close on September 17, 2025, is anticipated to generate approximately $2.0 million in gross proceeds. Palladium Capital Group, LLC is acting as the exclusive placement agent. The funds will be used for general working capital, including debt repayment and redemption of preferred stock. This offering is conducted under a shelf registration statement filed with the SEC.
PIPE/PO
growth-positive
NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical’s Intellectual Property Portfolio
NanoVibronix, Inc., a medical technology company, announced the issuance of a new U.S. patent for its subsidiary, ENvue Medical Holdings LLC. The patent, titled Insertion Device Positioning Guidance System and Method, enhances the companys competitive position in medical navigation technology. This patent protects proprietary systems for guiding the insertion of medical devices using electromagnetic positioning technology, improving real-time visualization and accuracy. The patent is seen as a significant milestone, reinforcing NanoVibronixs leadership in the field and supporting its growth strategy. The companys ENvue Navigation Platform is FDA 510(k) cleared for adult use, with potential future expansions.
growth-positive
NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology
NanoVibronix, Inc., a medical technology company, announced the issuance of a new U.S. patent for its subsidiary, ENvue Medical Holdings LLC. The patent covers a proprietary method for overlaying electromagnetic navigation data onto real-time medical imaging, enhancing the precision and efficiency of feeding tube and catheter placements. This development strengthens the companys intellectual property portfolio and positions it for expansion into the vascular navigation market. The ENvue Navigation Platform, which is FDA 510(k) cleared for adult use, provides real-time visualization of tube movement, supporting informed clinical decision-making. The patent is expected to bolster NanoVibronixs leadership in the feeding tube placement market and open new opportunities for growth.
Product Stage
growth-negative
NanoVibronix Announces Reverse Stock Split
NanoVibronix, Inc., a medical technology company, announced a reverse stock split of its common stock at a ratio of 1-for-10, effective August 11, 2025. The stock will begin trading on a split-adjusted basis on August 12, 2025. This move, approved by stockholders, aims to consolidate shares and adjust the trading price. The reverse split will reduce the number of outstanding shares from approximately 7.97 million to 796,887, affecting all stockholders uniformly without altering their percentage ownership, except for fractional shares which will be rounded up. The companys common stock will continue to trade on the Nasdaq under the symbol NAOV.
growth-positive
NanoVibronix Announces Financing of up to $50 Million Private Placement of Preferred Stock
NanoVibronix, Inc., a medical technology company, has entered into a definitive agreement with an institutional investor for the purchase and sale of Series H Convertible Preferred Stock. The initial closing is expected to generate approximately $8 million in gross proceeds, with a potential for an additional $40 million from the exercise of additional investment rights. The company plans to use $5 million of the net proceeds to redeem certain outstanding shares of its Series X Preferred Stock and the remainder for working capital. Palladium Capital Group, LLC is acting as the exclusive placement agent for this transaction.
Investment
growth-positive
NanoVibronix Announces ENvue Drive – First Intelligent Robotic Platform in Development for Bedside Feeding Tube and Vascular Line Navigation
NanoVibronix, Inc. has announced the launch of its ENvue Drive™ platform, a next-generation robotic development initiative within its ENvue Medical division. The platform aims to automate electromagnetic navigation for enteral and vascular access procedures, addressing the need for increased procedural volume with fewer hands at the bedside. The system is currently in engineering development and integrates with the companys FDA-cleared electromagnetic guidance technology. This initiative positions NanoVibronix to address a growing global demand for automated high-volume bedside procedures, driven by workforce shortages and increasing patient complexity. The market for enteral feeding devices and vascular access devices is projected to grow significantly by 2030.
Product Stage
growth-positive
NanoVibronix’s ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement
NanoVibronix, Inc., a medical technology company, announced that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems. These systems will aid in the bedside placement of nasoenteric feeding tubes, utilizing electromagnetic technology for real-time visualization. The agreement marks ENvues first formal adoption in the northeastern U.S. and reflects a trend among healthcare institutions to update their placement technologies. The ENvue System is FDA-cleared for adult use and is being deployed nationwide. This development is part of NanoVibronixs strategy to leverage emerging technologies and expand market opportunities.
CustomersProduct Stage
growth-positive
ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System
NanoVibronix, Inc., through its ENvue Medical division, has announced the granting of a new U.S. patent for its pediatric feeding tube guidance system. This patent strengthens ENvues intellectual property and supports its strategy to expand clinical use and pursue FDA 510(k) clearance for pediatric applications. The ENvue system, currently FDA-cleared for adults, uses electromagnetic tracking for real-time navigation, aiming to reduce reliance on confirmatory imaging. The pediatric market presents a significant opportunity, with over 1.5 million procedures annually in the U.S. alone. The patent reflects NanoVibronixs commitment to innovation and addressing unmet needs in enteral access for vulnerable populations.
Product Stage
growth-positive
NanoVibronix Announces CEO Transition
NanoVibronix, Inc., a medical technology company, announced the retirement of Brian Murphy as CEO, with Doron Besser taking over the role. This change follows the companys acquisition of ENvue Medical Holdings, a move aimed at enhancing growth and operational synergies. The acquisition, completed on February 14, 2025, is expected to expand NanoVibronixs reach in the global medical device market. The company remains focused on commercializing its therapeutic solutions and developing innovative medical products. The Board of Directors expressed gratitude to Murphy for his contributions and is optimistic about the companys future under Bessers leadership.
Management ChangesAcquisition
growth-positive
Major Louisiana Hospital Selects ENvue System for Feeding Tube Procedures
NanoVibronix, Inc., a medical technology company, announced that a major 420-bed acute care hospital in the Greater New Orleans area has adopted its ENvue Navigation Platform for adult feeding tube procedures. The ENvue System, which is FDA-cleared, provides real-time electromagnetic-guided placement, enhancing accuracy and patient safety. This marks the companys first entry into the Louisiana market, reflecting growing interest in electromagnetic guidance technology. The system has already been shipped to the hospital, with implementation scheduled soon. NanoVibronix focuses on non-invasive therapeutic technologies and plans further hospital implementations across the U.S.
Customers
growth-positive
NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants
NanoVibronix, Inc., a medical technology company, announced the closing of its underwritten public offering of Series G Convertible Preferred Stock and Warrants, raising approximately $10 million. The offering included 400,000 shares of Preferred Stock and Warrants to purchase up to 4,901,982 shares of common stock. The proceeds will be used to redeem outstanding debentures and partially repay an outstanding note, as well as for general corporate purposes. The offering was managed by Dawson James Securities, Inc. and was made pursuant to a registration statement declared effective by the SEC. This move is expected to positively impact the companys financial position.
PIPE/PO
growth-positive
NanoVibronix Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants
NanoVibronix, Inc., a medical technology company, announced the pricing of an underwritten public offering of its Series G Convertible Preferred Stock and Warrants to purchase common stock. The offering is expected to raise approximately $10 million in gross proceeds, which will be used for the redemption of outstanding debentures and general corporate purposes. Dawson James Securities, Inc. is the sole bookrunning manager for the offering. The public offering is made pursuant to a registration statement declared effective by the SEC. The closing of the offering is anticipated around May 19, 2025, subject to customary closing conditions.
PIPE/PO
growth-positive
NanoVibronix Announces Results from UroShield™ Case Series
NanoVibronix, Inc., a medical technology company, announced positive findings from a retrospective case series evaluating the UroShield™ system. Conducted by University Hospitals Coventry and Warwickshire Partnership NHS, the study showed significant reductions in catheter-associated urinary tract infections (CAUTIs), catheter blockages, and unplanned hospital visits. The UroShield device, which uses Surface Acoustic Wave (SAW) technology, demonstrated a 94% reduction in CAUTIs and blockages and a 92% decrease in hospital visits. These results reinforce previous studies and highlight the devices effectiveness in improving patient care and reducing healthcare costs. The findings will be presented at the Association for Continence Professionals annual conference. NanoVibronixs devices, including UroShield and PainShield, are designed for home use, enhancing patient comfort and quality of life.
Product Stage
growth-positive
NanoVibronix Regains Nasdaq Compliance
NanoVibronix, Inc., a medical technology company specializing in non-invasive therapeutic devices, announced that it has achieved full compliance with Nasdaqs listing criteria, including the $1.00 bid price and $2.5 million stockholders’ equity requirements. This compliance ensures the companys continued listing on The Nasdaq Capital Market, closing a previously disclosed listing matter. NanoVibronix develops medical devices using patented low-intensity surface acoustic wave (SAW) technology, with products like PainShield® and UroShield® designed for home use. The company will be under a Mandatory Panel Monitor until April 9, 2026. The article also highlights potential risks and uncertainties facing the company, including market acceptance, regulatory approvals, and competition. Despite these challenges, the compliance news is a positive development for NanoVibronix.
growth-positive
NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia
NanoVibronix, Inc., a medical technology company, announced the renewal and expansion of its distribution agreement with Dukehill Healthcare Pty Ltd. This agreement extends Dukehills distribution of NanoVibronixs UroShield device across all Australian states, following a surge in demand driven by a recent independent study highlighting the devices effectiveness. The studys findings are expected to boost sales and awareness of UroShield, which is designed to reduce catheter-associated complications. The partnership aims to enhance patient care and expand the devices reach in the Australian market. Dukehill will also promote UroShield at the upcoming National Conference on Incontinence in May 2025.
Partners
growth-positive
Why Nanovibronix Inc. (NAOV) Surged On Thursday?
Nanovibronix Inc. (NASDAQ:NAOV) experienced a significant stock surge, rising 36.5% to close at $4.45, driven by positive investor sentiment regarding its UroShield device. The device demonstrated efficacy in reducing catheter-associated urinary tract infections (UTI) by 86%, catheter blockages by 70%, and bladder irrigations by 82.8%. The companys proprietary low-intensity surface acoustic wave (SAW) technology allows for various medical applications, including biofilm disruption and pain relief. Despite the positive outlook for NAOV, the article suggests that some AI stocks may offer higher returns in a shorter timeframe.
growth-positive
Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal
NanoVibronix, Inc., a medical technology company, announced a study published in The Australian and New Zealand Continence Journal highlighting the effectiveness of its UroShield® device. The study found significant reductions in catheter-associated urinary tract infections (CAUTIs) and blockages, leading to improved patient comfort and reduced healthcare costs. The UroShield® device demonstrated an 86% reduction in UTI incidence and a 70% reduction in catheter blockages. The study also reported a 63.5% reduction in resource costs over five months. The findings suggest that UroShield® can enhance patient care and reduce healthcare resource expenditure, indicating its potential for broader adoption in healthcare settings.
growth-negative
NanoVibronix Announces Reverse Stock Split
NanoVibronix, Inc., a medical technology company, announced a reverse stock split of its common stock at a ratio of 1-for-11. This change will take effect on March 13, 2025, and the stock will begin trading on a split-adjusted basis on March 14, 2025. The reverse stock split, approved by stockholders on February 24, 2025, aims to consolidate shares, reducing the number of outstanding shares from 8,716,327 to approximately 792,394. The split will not alter any stockholder’s percentage interest in the company, except for fractional shares, which will be rounded up. The companys stock will continue to trade on the Nasdaq Capital Market under the symbol NAOV.
growth-positive
NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp.
NanoVibronix, Inc., a medical technology company, announced the acquisition of ENvue Medical Holdings Corp., a leader in enteral feeding solutions. This strategic acquisition aims to enhance NanoVibronixs market position in the medical device sector by integrating ENvues innovative technology. The transaction, structured as a stock-for-stock exchange, is expected to create a broader commercial platform, improve operational efficiencies, and accelerate growth. The combined expertise and market presence of both companies will allow them to reach more healthcare providers with advanced solutions, ultimately improving patient outcomes and creating long-term value for shareholders.
Acquisition
growth-positive
NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes
NanoVibronix, Inc., a medical device company, announced the completion of the design phase for its next-generation PainShield® and UroShield® devices. The company, which specializes in portable ultrasonic therapeutic devices, is advancing to the verification and testing phase. The new designs aim to reduce assembly costs, enhance user experience, and ensure regulatory compliance. The prototypes were delivered on time and within budget, marking a significant milestone towards broader adoption by the healthcare community. The company is focused on operational improvements and product evolution to benefit patients. The development is part of NanoVibronixs strategy to future-proof its products and streamline manufacturing processes.
Product Stage
growth-positive
Transforming catheter care: NanoVibronix completes successful UroShield US trial
NanoVibronix, a medical device company specializing in therapeutic ultrasound technology, has successfully completed the pilot phase of its UroShield clinical trial in the US. The trial met its primary objectives, paving the way for expanded clinical evaluations and regulatory engagement. The UroShield device, which prevents bacterial colonization and biofilm formation, addresses catheter-associated complications. The global urology therapy device market is projected to grow, driven by technological advancements and an aging population. NanoVibronix plans to secure FDA clearance and scale production to meet anticipated demand in the US, positioning UroShield as a potential cornerstone in urinary care.
Product StageFDA approved/pending approval
growth-positive
NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan
NanoVibronix, Inc., a medical device company, announced the successful completion of the first phase of a Randomized Control Trial for its UroShield® device, conducted by researchers at the University of Michigan. This phase, primarily involving nursing home residents, aimed to assess the devices impact on reducing urinary tract infections and catheter-related issues. The studys success paves the way for a full trial expected to commence in 2025. The company is also preparing for the U.S. launch of UroShield, pending FDA 510K clearance. NanoVibronixs technology utilizes low-frequency ultrasound waves for medical applications, including pain relief and biofilm disruption.
Product Stage
growth-positive
NanoVibronix “achieves goals” of US trial pilot phase with UroShield
NanoVibronix has completed the pilot phase of a randomized control trial for its UroShield device, which is designed to prevent catheter-associated urinary tract infections. The pilot phase, conducted at the University of Michigan, aimed to refine recruitment and retention strategies and assess intervention and data collection tools. With the pilot phase goals achieved, the company plans to advance to the full study, enrolling an estimated 300 participants. UroShield, which creates an acoustic shield to prevent bacterial colonization, is CE marked and available on Englands NHS. The company is preparing for U.S. market commercialization, pending FDA 510K clearance. Shares rose 4.7% following the announcement.
Product StageFDA approved/pending approval
growth-positive
NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement
NanoVibronix, Inc., a medical device company, has renewed its exclusive distribution agreement with Ultra Pain Products, Inc. (UPPI) for its PainShield product for another five years. The agreement includes a minimum purchase commitment valued at $12 million. This renewal highlights the strong partnership between the two companies, focusing on non-opioid pain management solutions. UPPIs growth and transition into manufacturing align with NanoVibronixs goals, making them an ideal partner. The collaboration aims to enhance the non-opioid treatment landscape in the U.S., providing advanced solutions for injury recovery and pain management. The partnership underscores both companies commitment to innovation and patient empowerment.
Partners
growth-negative
NanoVibronix Third Quarter 2024 Earnings: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023)
The article discusses the financial performance of NanoVibronix, highlighting a decrease in revenue to US$376.0k, down 18% from the third quarter of 2023, and a net loss of US$998.0k, which widened by 37% from the previous quarter. The loss per share stands at US$0.36. Additionally, NanoVibronix shares have decreased by 1.5% over the past week. The article mentions five warning signs for the company, three of which are significant. The analysis is based on historical data and analyst forecasts, and it is not intended as financial advice.
growth-positive
NanoVibronix Provides Business Update
NanoVibronix, Inc., a medical device company, announced significant progress in expanding the distribution of its products, particularly the UroShield device. The company has signed a letter of intent with Kriel Technology Group (Pty) Ltd to explore distribution opportunities in South Africa. This partnership aims to increase market penetration and address catheter-associated urinary tract infections (CAUTIs). Independent research presented at major medical conferences has validated the effectiveness of UroShield in reducing CAUTIs, enhancing patient quality of life, and providing economic benefits to healthcare systems. The company is optimistic about finalizing a distribution agreement with KrielTech, which would mark its entry into the South African market.
Partners
NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany
NanoVibronix Signs Letter of Intent with Potential New Distributor
NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders
Growth-Positive
NanoVibronix Second Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.65 loss in 2Q 2023)
NanoVibronix has reported its second quarter 2024 results, showing a revenue of US$817.0k, up 178% from the same period in 2023. The companys net loss has also narrowed by 36% to US$688.0k, and its loss per share has improved from US$0.65 in 2Q 2023 to US$0.25 in 2Q 2024. NanoVibronixs shares are up 7.1% from a week ago. However, the article also mentions that there are 4 warning signs for NanoVibronix, 3 of which are potentially serious.
Customers
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan
NanoVibronix Issues Letter to Stockholders
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs’ FSS Contract Award
growth-positive
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
Planet MicroCap is hosting the Planet MicroCap Showcase: VEGAS from April 30 to May 2, 2024. The event will feature 96 MicroCap public and private companies presenting at the Paris Hotel & Casino in Las Vegas. The showcase begins with a MicroCap Investing Workshop featuring financial influencers, investors, fund managers, and key opinion leaders. This will be followed by company presentations and 1x1 meetings. The event aims to cultivate an active and engaged community interested in the MicroCap market.
Customers
growth-positive
NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024
NanoVibronix, Inc., a medical device company, has announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024. The company produces the UroShield, PainShield and WoundShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices. The presentation will be hosted by Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. The company is also offering 1x1 investor meetings at the conference venue.
CustomersPartners
NanoVibronix Issues Letter to Stockholders
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
NanoVibronix Featured in Your Bladder Health Magazine
NanoVibronix Featured in Your Bladder Health Magazine
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
NanoVibronix Regains Nasdaq Compliance
NanoVibronix Issues Letter to Shareholders
NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
growth-positive
Why Is NanoVibronix Stock Trading Higher Today?
NanoVibronix Inc has reported positive outcomes from a UroShield study conducted at the University of Southampton. The study found that UroShield had a positive effect on catheter-associated urinary tract infections and catheter blockage, with a third of patients reporting a reduction in the frequency of blockages. The device uses ultrasonic waves to create an acoustic shield on the surfaces of a catheter, preventing bacterial attachment and biofilm formation, and potentially reducing the need for antibiotics. Following the announcement, shares in NanoVibronix rose by 95.90%.
Investment
NanoVibronix Cites Positive Results from Independent Testing of UroShield
NanoVibronix Responds to CMS’ Determination for PainShield
NanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus
NanoVibronix Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard
NanoVibronix Issues Letter to Shareholders
NanoVibronix Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services (CMS)
NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra
NanoVibronix Announces Positive Results from Independent Product Trial of UroShield for Patients with a Spinal Cord Injury
NanoVibronix Regains Nasdaq Compliance
NanoVibronix to Launch Rental Program for PainShield and UroShield
NanoVibronix Announces Reverse Stock Split
NanoVibronix Provides Update on Expanding Access to PainShield
NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today
NanoVibronix Announces Partnership with Peak Medical, Ltd.
Growth-negative
Shareholders Will Likely Find NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Compensation Acceptable
Shareholders of NanoVibronix, Inc. are concerned about the companys performance and CEO Brian Murphys compensation. The companys AGM is scheduled for December 15, 2022, where shareholders can vote on resolutions including executive remuneration. Despite the companys earnings per share (EPS) increasing by 27% a year over the past three years and its revenue up by 61% in the last year, the total shareholder return has been -87% over three years. CEO Murphys total annual compensation was $405k for the year to December 2021, an 11% increase from the previous year.
Management Changes
NanoVibronix Announces Closing of $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NanoVibronix Announces $2.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus
Growth-Negative
NanoVibronix Third Quarter 2022 Earnings: US$0.034 loss per share (vs US$0.26 loss in 3Q 2021)
NanoVibronix has reported its third quarter results for 2022, revealing a significant decline in revenue and a net loss. The companys revenue was down 81% from the third quarter of 2021, at US$97.0k. The net loss was US$955.0k, although this was an improvement from the previous year, with the loss narrowing by 86%. The loss per share also improved, from US$0.26 in 3Q 2021 to US$0.034. Despite these figures, NanoVibronix shares are down 1.5% from a week ago.
Customers
growth-positive
Interim Results Of NanoVibronix's Uroshield Show Beneficial Effects For Patients
NanoVibronix Inc has announced interim results from its UK clinical study for UroShield, a disposable ultrasound device designed to reduce biofilm on catheter surfaces. The initial results suggest that the device has potential beneficial effects on the urinary and catheter microbiome. Most patients using the UroShield reported fewer catheter blockages and infections. The study was initiated in April 2021 to provide the necessary clinical evidence for FDA clearance.
CustomersInvestment
NanoVibronix Announces Interim Results of Clinical Study for UroShield
NanoVibronix Provides Business Update in Letter to Shareholders
NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement
NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract
growth-positive
NanoVibronix +61% on distributtion deal for PainShield device (NASDAQ:NAOV)
NanoVibronix has signed a two-year exclusive agreement with Ultra Pain Products for the distribution of its PainShield ultrasound devices and components through Durable Medical Equipment Distributors in the U.S. The agreement, which has led to a 61% premarket surge in NanoVibronixs shares, includes minimum annual quantities and bi-monthly order quantity minimums in the first year, shifting to quarterly order minimums in the second year. The device is touted as an effective alternative to drugs for pain management.
PartnersCustomers
growth-positive
NanoVibronix Signs Two Year, Exclusive Distribution Agreement for PainShield
NanoVibronix, Inc. has entered into a two-year exclusive agreement with Ultra Pain Products, Inc. for the distribution of NanoVibronixs proprietary PainShield devices and components throughout the United States. The partnership aims to deliver an opioid-free pain management solution to healthcare providers and their patients. The agreement comes amidst the COVID-19 pandemic, providing a unique opportunity to apply strengths in sales, marketing and reimbursement to bring the PainShield product to the U.S. and further advance the treatment of patients in a safe, remote setting.
Partners
growth-positive
NanoVibronix Fulfills its First Private Label Partnership with Medisana and Receives Award for PainShield PT 100 Quality
NanoVibronix, Inc., a medical device company, has announced that its newly introduced PainShield PT 100 ultrasound therapy device has received the Plus X Award 2020 in the categories of high quality, design, ease of use and functionality. The device, which is sold directly and exclusively by Medisana outside the United States, is a portable therapeutic ultrasound device for the treatment of pain and soft tissue injuries. The award is a clear affirmation of the design, quality and innovation behind the PainShield technology, according to Brian Murphy, CEO of NanoVibronix.
CustomersPartners
growth-positive
NanoVibronix Announces Planned Launch of CBD Patch and Cream for PainShield® Designed to Amplify Therapeutic Effect
NanoVibronix, Inc., a medical device company, announced that it is developing a cannabidiol (CBD) patch and cream utilizing a proprietary and nanoparticle-based infusion process. The CBD patch and cream will be available in combination with PainShield as PainShield CBD. The company aims to demonstrate that coupling the infused patch and cream with PainShield will increase absorption and may provide sustained pain relief for up to 24 hours. NanoVibronix is partnering with Saralex Group Inc., which will manage the regulatory approval process and launch PainShield CBD in Canada and the European Union.
PartnersExpand
growth-positive
NanoVibronix Enters Collaboration Agreement with Fritz Clinic to Offer PainShield® as an Alternative to Opioids for Pain Management
NanoVibronix, Inc., a medical device company, has announced a collaboration agreement with the Fritz Clinic, a wellness and preventative medicine clinic with seven locations in North America. The Fritz Clinic plans to offer its patients NanoVibronix’s PainShield as an alternative treatment option for pain, and to aid in decreasing the dependency on opioids for pain relief. PainShield is an ultrasound device that treats pain and induces soft tissue healing in a targeted area. It can be used by patients at home or work or in a clinical setting and can be used even while the patient is sleeping.
PartnersCustomers
growth-positive
NanoVibronix Announces Expanded Agreement with MDS Pharm Ltd. to Include Distribution of UroShield® in Israel
NanoVibronix, Inc., a medical device company, has expanded its distribution agreement with MDS Pharm Ltd., its current PainShield and WoundShield distributor in Israel. This agreement will allow MDS Pharm Ltd. to market and distribute NanoVibronixs UroShield in Israel. UroShield is an ultrasound-based product designed to prevent bacterial colonization and biofilm on indwelling urinary catheters, increasing antibiotic efficacy and reducing the incidence of catheter-associated urinary tract infections. The CEO of NanoVibronix expressed excitement about the expansion, citing the significant market for their products in Israel.
PartnersExpand
growth-positive
NanoVibronix Signs Major Distributor in India for UroShield®
NanoVibronix, Inc, a medical device company, has announced a new distribution agreement for UroShield with Cnergy Group of Companies in partnership with Morulaa HealthTech. Cnergy is a leading medical device distributor in India. UroShield is an ultrasound-based product designed to prevent bacterial colonization and biofilm on indwelling urinary catheters, reducing the incidence of catheter-associated urinary tract infections. The product is also intended to decrease pain and discomfort associated with urinary catheter use. The partnership aims to address the significant need for a noninvasive solution for the prevention of urinary tract infections in India.
PartnersExpand
growth-positive
NanoVibronix Signs with Exclusive Distributor in Switzerland for UroShield®
NanoVibronix, Inc, a medical device company, has announced a new distribution agreement for UroShield with Stöckli Medical AG, a Swiss medical device company. UroShield is a small external medical device developed to prevent bacterial colonization and biofilm formation on both urethral and suprapubic catheters. The CEO of NanoVibronix, Brian Murphy, expressed his pleasure at partnering with Stockli to distribute UroShield, citing them as a leading distributor of technology platforms and innovative clinical approaches in Switzerland.
Partners
growth-positive
NanoVibronix Announces Selection of Leading International Contract Manufacturer to Support Rapid Scale-up, Lower Price Points and Enhance Profitability
NanoVibronix, Inc. has appointed Quasar as its contract manufacturer for its medical devices including PainShield, UroShield, and WoundShield. Quasar is a medical device manufacturer with over 30 years of experience and is ISO9001 and ISO13485 certified. The move is expected to generate cost savings for NanoVibronix, allowing it to lower its selling price, increase production to meet revenue expectations, open additional markets, and improve profitability.
PartnersManagement Changes
growth-positive
NanoVibronix Announces Publication of Study Measuring the Effect of Surface Acoustic Waves on Bacterial Load and Preventing Catheter-Associated Urinary Tract Infections
NanoVibronix, Inc. has announced the publication of an independent study showing the effectiveness of its UroShield device in reducing bacterial load and preventing catheter-associated urinary tract infections (CAUTI). The study, published in the December 2018 issue of Medical & Surgical Urology, showed that UroShield reduced Colony Forming Units (CFU) count from >100,000 to 10,000 CFU or less in 25 of 29 patients in the treatment group. There were no reported infections in the treatment group. The company believes UroShield has the potential to save lives and significantly reduce healthcare costs.
Customers
growth-positive
NanoVibronix Announces Exclusive Agreement for Distribution of PainShield® and WoundShield® in Israel
NanoVibronix, Inc., a medical device company, has entered into an exclusive agreement with M.D.S. Pharm Ltd. to market and distribute NanoVibronix’s PainShield® and WoundShield® in Israel. M.D.S. Pharm Ltd. is a leading distributor of medical equipment for home-care and self-diagnostics. The partnership will leverage M.D.S.s established distribution network in Israel that includes health insurance providers, private pharmacies, health stores, beautician centers, private clinics, and leading health websites.
Partners
NanoVibronix Announces Positive Response to UroShield(TM) Presentation at the Infection Prevention and Control 2018 London Conference
growth-positive
NanoVibronix inks UK UroShield distro deal with IMS Ultrasound
NanoVibronix has signed an exclusive distribution deal with the UKs IMS Ultrasound for its UroShield device, which is designed to prevent catheter-acquired urinary tract infections (CAUTIs). The device is also designed to reduce pain and discomfort associated with urinary catheter use. As part of the deal, IMS Ultrasound will fund a clinical study in association with the UKs National Health Service. The UroShield device has already received European marketing clearance.
PartnersExpand
growth-positive
NanoVibronix files to raise $10m on Nasdaq
NanoVibronix, a company that develops vibrating medical devices, is planning to raise up to $10 million in a financing round. The company aims to use the funds to reach the main Nasdaq listing. As part of a company shakeup, it plans to move its headquarters to the US, while leaving its R&D and production departments in Israel. Despite its relative seniority in the market, the companys revenue has been minimal, posting an $880,000 loss in the first quarter. The company raised $1 million in bonds in March.
InvestmentExpand
Press Releases Archive - Digital Journal
Tegal Makes Strategic Investment in NanoVibronix, Innovator in Global Wound Care and Catheter Markets
NanoVibronix Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 13 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
NanoVibronix Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 513483164 |
| Crunchbase | nanovibronix |
| Phone | +97248200581 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-12-05T00:00:00.000Z |
| Created | 2014-07-20T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NASDAQ on Apr, 2014<br> |